Re: ANDS results
Dew, would you say the data is not that big of a deal just because it's so preliminary? We are only talking about 8 patients with 3 days' dosing data.
Also, I think you said separately before in reference to ACHN that it's not so much the potency with HCV drugs as it is the safety. So, the fact that it was so potent after just a few days means very little given that you can't really tell much of anything about safety in 3 days. And, with respect to potency, we don't know anything about possible viral rebound at a later point. Even if it's extremely potent at the start of treatment, any type of viral rebound later would negate that I would assume. So, we just need to see longer-term results. Notwithstanding, this is certainly good news for ANDS.
Market Data 
Markets 
AI
